LEXINGTON, Mass., April 4, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced the presentation of data in a poster session at the American Association for Cancer Research (AACR) Annual Meeting 2012 in Chicago, Illinois. The poster presentation, titled “Antitumor Activity of CUDC-907, a Dual PI3K and HDAC Inhibitor in Hematological Cancer Models”, was presented by Rudi Bao, M.D., Ph.D., Curis’ Senior Director of Oncology on April 3rd.
